|
HIV-1 element
|
Total interactions
|
Interactions with drug target genes
|
Corrected p
|
|---|
|
Env-gp120
|
856 (22%)
|
239 (29%)
|
5.85 × 10-6
|
|
Integrase
|
102 (3%)
|
5 (1%)
|
7.15 × 10-4
|
|
Rev
|
109 (3%)
|
7 (1%)
|
1.36 × 10-3
|
|
Env-gp41
|
190 (5%)
|
58 (7%)
|
4.65 × 10-3
|
|
Tat
|
1394 (35%)
|
249 (30%)
|
2.50 × 10-2
|
|
Capsid
|
45 (1%)
|
16 (2%)
|
6.23 × 10-2
|
|
Vif
|
77 (2%)
|
8 (1%)
|
6.57 × 10-2
|
|
Nef
|
302 (8%)
|
78 (10%)
|
7.60 × 10-2
|
|
Pol
|
1 (< 1%)
|
0 (0%)
|
0.238
|
|
Vpr
|
275 (7%)
|
47 (6%)
|
0.173
|
|
Env-gp160
|
213 (5%)
|
49 (6%)
|
0.432
|
|
Env-gp41
|
190 (5%)
|
58 (7%)
|
1.07 × 10-2
|
|
Rev
|
109 (3%)
|
7 (1%)
|
4.50 × 10-3
|
|
Integrase
|
102 (3%)
|
5 (1%)
|
2.61 × 10-3
|
|
Matrix
|
95 (2%)
|
15 (2%)
|
0.399
|
|
Retropepsin
|
89 (2%)
|
15 (2%)
|
0.506
|
|
Vif
|
77 (2%)
|
8 (1%)
|
0.120
|
|
Gag
|
72 (2%)
|
15 (2%)
|
0.889
|
|
Reverse transcriptase
|
45 (1%)
|
8 (1%)
|
0.605
|
|
Vpu
|
27 (1%)
|
5 (1%)
|
0.667
|
|
Nucleocapsid
|
26 (1%)
|
4 (< 1%)
|
0.486
|
|
p6
|
18 (< 1%)
|
2 (< 1%)
|
0.386
|
|
p1
|
3 (< 1%)
|
0 (0%)
|
0.253
|
- The proportion of interactions that HIV-1 has with the products of genes that also encode drug targets, compared to total interactions, grouped by HIV-1 element are shown. The statistical significance of the difference in expected and actual figures, indicated by p-values, were calculated in JNets using two-tailed Chi-square tests, corrected for multiple testing using the Benjamini and Hochberg method [15]. Using a p cutoff of 0.05, we found significantly more Env-gp120 and Env-gp41 interactions and significantly fewer Tat, Integrase and Rev interactions among drug target genes, than would be expected at random.
